or peritoneal or fallopian tube adenocarcinoma histologically confirmed
Progression or relapse within 12 months after the end of first line of platin based chemotherapy
association in first line with other anticancer agent is allowed (taxanes, anthracyclines, alkylants or gemcitabine) and with an anti-angiogenic (bevacizumab, sunitinib).
intra-peritoneal chemotherapy in first line is possible
No previous treatment with HER inhibitors (ex : gefitinib)
HER status not necessary
measurable lesions (RECIST criteria). and/or CA125 value higher than 2 fold the normal value or CA125 higher than 2 fold nadir value (if no normalized) proved by two samples distant of 1 month
OMS inferior or equal 2.
biological parameters as follow: creatininemia ≤ 150 µmol/L or clearance ≥ 50 mL/min,bilirubin ≤ 1,5 LNS,transaminases and or alcalin phosphatases ≤ 2 LNS without hepatic metastasis or ≤ 3 LNS if hepatic metastasis,neutrophils ≥ 1,5.109/L,plaquettes ≥ 100.109/L.
normal FEV
No previous treatment by chemotherapy, hormonotherapy, immunotherapy or radiotherapy within 4 weeks before inclusion
No concomitant treatment forbidden with lapatinib.
No previous treatment by Amiodarone in 6 months before inclusion
signed informed consent
You may not be if
Previous treatment with :
* intensive chemotherapy with autograft
* two lignes of chemotherapy
* previous total abdominal irradiation
* previous chemotherapy with anti-HER treatment
History of brain or meningitis metastasis uncontrolled.
Malignancies except for adequately treated carcinoma in situ of the cervix and/or basal cell skin cancer.
uncontrolled infectious pathology
uncontrolled cardiovascular disease
Patients with an active intestinal occlusion not permit oral treatment
known hypersensibility to topotecan and its excipients
Woman of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period
